Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150490 | 0.86 | TSHR (0.40) | HTR1ASLC6A3HDAC1HDAC2NOS1 | |
| SCHEMBL23157787 | 0.83 | IDO1 (0.53) | IDO1AGXT | |
| SCHEMBL19240348 | 0.82 | HTR1A (0.39) | HTR1ASLC6A3HDAC1HDAC2NOS1 | |
| SCHEMBL14270237 | 0.80 | SIGMAR1 (0.44) | HTR1ANOS1IDO1NOX1SIGMAR1 | |
| SCHEMBL16749885 | 0.80 | PDE4A (0.43) | HTR1ASLC6A3NOS1NOX1SIGMAR1 | |
| SCHEMBL15569061 | 0.79 | SLC6A3 (0.36) | HTR1ASLC6A3HDAC1HDAC2NOS1 | |
| SCHEMBL22683759 | 0.78 | CYP51A1 (0.42) | SLC6A3NOX1 | |
| SCHEMBL23270659 | 0.77 | HTR1A (0.40) | HTR1ASLC6A3NOS1NOX1SIGMAR1 | |
| SCHEMBL20552581 | 0.77 | NOS1 (0.53) | NOS1NOS2 | |
| SCHEMBL17208761 | 0.77 | HTR1A (0.40) | HTR1ASLC6A3NOS1NOX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | HTR1A 925/4885SLC6A3 3419/4885HDAC1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.